ALX Oncology (ALXO) Competitors $0.47 0.00 (-0.49%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$0.48 +0.02 (+3.97%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALXO vs. MCRB, IOBT, OKYO, WHWK, SAVA, XBIT, VIRI, ADAG, BYSI, and OCXShould you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Seres Therapeutics (MCRB), IO Biotech (IOBT), OKYO Pharma (OKYO), Whitehawk Therapeutics (WHWK), Cassava Sciences (SAVA), XBiotech (XBIT), Virios Therapeutics (VIRI), Adagene (ADAG), BeyondSpring (BYSI), and OncoCyte (OCX). These companies are all part of the "pharmaceutical products" industry. ALX Oncology vs. Its Competitors Seres Therapeutics IO Biotech OKYO Pharma Whitehawk Therapeutics Cassava Sciences XBiotech Virios Therapeutics Adagene BeyondSpring OncoCyte ALX Oncology (NASDAQ:ALXO) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability. Is ALXO or MCRB more profitable? ALX Oncology's return on equity of -104.43% beat Seres Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -104.43% -77.74% Seres Therapeutics N/A -41,084.76%-55.87% Does the media favor ALXO or MCRB? In the previous week, ALX Oncology had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 3 mentions for ALX Oncology and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 1.89 beat ALX Oncology's score of 0.22 indicating that Seres Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment ALX Oncology Neutral Seres Therapeutics Very Positive Do analysts prefer ALXO or MCRB? ALX Oncology presently has a consensus target price of $3.30, suggesting a potential upside of 607.40%. Seres Therapeutics has a consensus target price of $73.67, suggesting a potential upside of 402.16%. Given ALX Oncology's stronger consensus rating and higher probable upside, equities research analysts clearly believe ALX Oncology is more favorable than Seres Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Seres Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 Which has more volatility & risk, ALXO or MCRB? ALX Oncology has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the S&P 500. Which has higher valuation & earnings, ALXO or MCRB? Seres Therapeutics has higher revenue and earnings than ALX Oncology. Seres Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$134.85M-$2.47-0.19Seres Therapeutics$126.32M1.01$140K-$4.60-3.19 Do insiders and institutionals have more ownership in ALXO or MCRB? 98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 21.0% of ALX Oncology shares are held by insiders. Comparatively, 4.7% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryALX Oncology beats Seres Therapeutics on 9 of the 14 factors compared between the two stocks. Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALXO vs. The Competition Export to ExcelMetricALX OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.03M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.1920.2228.5419.58Price / SalesN/A298.23430.1194.56Price / CashN/A43.1536.0257.93Price / Book0.227.568.145.54Net Income-$134.85M-$55.11M$3.24B$257.73M7 Day Performance-6.76%3.81%0.17%-0.08%1 Month Performance-12.25%11.60%5.95%8.09%1 Year Performance-94.26%-2.11%26.22%13.02% ALX Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALXOALX Oncology3.5425 of 5 stars$0.47-0.5%$3.30+607.4%-94.2%$25.03MN/A-0.1940Gap DownMCRBSeres Therapeutics3.4421 of 5 stars$10.85-8.6%$73.67+579.0%-38.4%$94.72M$126.32M-2.36330Positive NewsGap DownIOBTIO Biotech3.624 of 5 stars$1.43-4.0%$9.33+552.7%+23.2%$94.21MN/A-0.9630OKYOOKYO Pharma3.3213 of 5 stars$2.82+1.4%$7.00+148.2%+73.0%$94.06MN/A0.007Gap UpWHWKWhitehawk TherapeuticsN/A$1.98-0.5%N/AN/A$93.28M$25.98M12.3840SAVACassava Sciences4.272 of 5 stars$1.93-4.0%$54.50+2,723.8%-83.3%$93.24MN/A-1.2930Positive NewsXBITXBiotech1.9166 of 5 stars$3.05-4.1%N/A-56.3%$92.99M$4.01M-2.36100News CoverageVIRIVirios TherapeuticsN/A$4.80-0.6%$5.00+4.2%+1,981.1%$92.44MN/A-17.785ADAGAdagene2.4974 of 5 stars$1.95+5.4%$8.00+310.3%-30.4%$91.86M$103.20K0.00260News CoverageUpcoming EarningsGap UpBYSIBeyondSpringN/A$2.27+1.8%N/A+2.7%$91.53M$1.75M0.0080Gap UpOCXOncoCyte1.2384 of 5 stars$3.18+16.3%$6.06+90.9%-5.5%$90.80M$3.84M-0.90120 Related Companies and Tools Related Companies Seres Therapeutics Competitors IO Biotech Competitors OKYO Pharma Competitors Whitehawk Therapeutics Competitors Cassava Sciences Competitors XBiotech Competitors Virios Therapeutics Competitors Adagene Competitors BeyondSpring Competitors OncoCyte Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALXO) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
